249
Participants
Start Date
January 28, 2016
Primary Completion Date
November 23, 2022
Study Completion Date
November 23, 2022
PF-0791800 (TTI-621)
Monotherapy
PF-07901800 (TTI-621) plus Rituximab
Combination therapy
PF-07901800 (TTI-621) plus Nivolumab
Combination therapy
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
NYU Investigational Pharmacy, New York
NYU Langone Health (Tisch Hospital), New York
Memorial Sloan Kettering Cancer Center-Clinical Trails Office, New York
Columbia Univeristy, New York
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care, New York
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion, New York
Columbia University Medical Center., New York
Memorial Sloan Kettering Cancer Center, New York
Memorial Sloan Kettering Cancer Center Westchester, Harrison
University of Pittsburgh Medical Center Presbyterian Shadyside, Pittsburgh
University of Pittsburgh Medical Center, Pittsburgh
Mayo Clinic Jacksonville, Jacksonville
Mayo Clinic, Jacksonville
Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus, Tampa
Moffitt Cancer Center, Tampa
Centennial Medical Center, Nashville
Sarah Cannon Research Institute (Pharmacy), Nashville
Tennessee Oncology PLLC, Nashville
Tennessee Oncology, PLLC, Nashville
Tennessee Oncology, Nashville
Cleveland Clinic Taussig Cancer Center, Cleveland
Cleveland Clinic, Cleveland
Covance Biorepository, Greenfield
Mayo Clinic, Rochester
The University of Texas MD Anderson Cancer Center, Houston
University of Texas MD Anderson Cancer Center, Cancer Prevention Center, Houston
University of Texas MD Anderson Cancer Center, Melanoma and Skin Clinic, Houston
University of Texas MD Anderson Cancer Center, Houston
Myriad RMB Inc, Austin
Colorado Blood Cancer Institute, Denver
Presbyterian/St.Luke's Medical Center, Denver
City of Hope National Medical Center, Duarte
City of Hope, Duarte
Freidenrich Center for Translational Research (CTRU), Palo Alto
Stanford Cancer Institute, Palo Alto
Oregon Health & Science University-Research Pharmacy Services, Portland
Oregon Health & Science University, Portland
Oregon Health and Sciences University, Portland
Seattle Cancer Care Alliance, Seattle
University of Washington - Seattle Cancer Care Alliance, Seattle
University of Washington Medical Center, Seattle
Hackensack Meridian Health John Theurer Cancer Center, Hackensack
Hackensack UMC, Hackensack
The John Theurer Cancer Center at Hackensack UMC, Hackensack
Memorial Sloan Kettering Cancer Center- Monmouth, Middletown
Fairmont Medical Building, Suite 810, Vancouver
British Columbia Cancer Agency, Vancouver
Princess Margaret Cancer Center, Toronto
University Health Network - Princess Margaret Cancer Centre, Toronto
Lead Sponsor
Pfizer
INDUSTRY